Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRx0237 in Mild to Moderate Alzheimer's Disease
NCT01626391Phase 2Terminated
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Sep 2012
- Primary completion
- Mar 2013
- Countries
- 2
01
Overview
A Phase 2 trial of hydromethylthionine mesylate in Alzheimer's disease (AD), sponsored by TauRx Therapeutics Ltd. Started Sep 2012; status: terminated.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01626391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01626391.